Statin use before and after acute ischemic stroke onset improves neurological outcome

References

• Rosamond W, Flegal K, Furie K et al. Heart disease and stroke statistics – 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation117(4), E25–E146 (2008).
   PubMed Web of Science ®Google Scholar
• The National Institute of Neurological Disorders and Stroke rtPA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rtPA Stroke Study Group. N. Engl. J. Med.333(24), 1581–1587 (1995).
   PubMed Web of Science ®Google Scholar
• Hacke W, Kaste M, Fieschi C et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA274(13), 1017–1025 (1995).
   PubMed Web of Science ®Google Scholar
• Hacke W, Kaste M, Bluhmki E et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N. Engl. J. Med.359(13), 1317–1329 (2008)
   PubMed Web of Science ®Google Scholar
• Laufs U, Liao JK. Rapid effects of statins: from prophylaxis to therapy for ischemic stroke. Artherioscler. Thromb. Vasc. Biol.23(2), 156–157 (2003).
   PubMed Web of Science ®Google Scholar
• Amarenco P, Labreuche J, Lavallee P et al. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke35(12), 2902–2909 (2004).
   PubMed Web of Science ®Google Scholar
• Athyros VG, Kakafika AI, Tziomalos K et al. Statins for the prevention of first or recurrent stroke. Curr. Vasc. Pharmacol.6(2), 124–133 (2008).
   PubMed Web of Science ®Google Scholar
• Nassief A, Marsh JD. Statin therapy for stroke prevention. Stroke39(3), 1042–1048 (2008).
   PubMed Web of Science ®Google Scholar
• Paciaroni M, Hennerici M, Agnelli G et al. Statins and stroke prevention. Cerebrovasc. Dis.24(2–3), 170–182 (2007).
   Google Scholar
• Amarenco P, Bogousslavsky J, Callahan A 3rd et al. Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N. Engl. J. Med.355(6), 549–559 (2006).
   PubMed Web of Science ®Google Scholar
• Parnetti L, Caso V, Lanari A et al. Stroke prevention and statin treatment. Clin. Exp. Hypertens.28(3–4), 335–344 (2006).
   PubMed Web of Science ®Google Scholar
• Collins R, Armitage J, Parish S et al; Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet363(9411), 757–767 (2004).
   PubMed Web of Science ®Google Scholar
• Sever PS, Dahlöf B, Poulter NR et al; ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet361(9364), 1149–1158 (2003).
   PubMed Web of Science ®Google Scholar
• Byington RP, Davis BR, Plehn JF et al. Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project. Circulation103(3), 387–392 (2001).
   PubMed Web of Science ®Google Scholar
• Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA279(20), 1643–1650 (1998).
   PubMed Web of Science ®Google Scholar
• Blauw GJ, Lagaay AM, Smelt AH et al.Stroke statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. Stroke (5), 946–950 (1997).
   Google Scholar
• Corvol JC, Bouzamondo A, Sirol M et al. Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials. Arch. Intern. Med.163(6), 669–676 (2003).
   PubMed Web of Science ®Google Scholar
• Amarenco P. Hypercholesterolemia, lipid-lowering agents, and the risk for brain infarction. Neurology57(5 Suppl. 2), S35–S44 (2001).
   PubMedGoogle Scholar
• George SJ, Dhond AJ, Alderson SM, Ezekowitz MD. Neuroprotective effects of statins may not be related to total and low-density lipoprotein cholesterol lowering. Am. J. Cardiol.90(11), 1237–1239 (2002).
   Google Scholar
• Sanossian N, Ovbiagele B. Drug insight: translating evidence on statin therapy into clinical benefits. Nat. Clin. Pract. Neurol.4(1), 43–49 (2008).
   Google Scholar
• Switzer JA, Hess DC. Statins in stroke: prevention, protection and recovery. Expert Rev. Neurother.6(2), 195–202 (2006).
   PubMedGoogle Scholar
• Moonis M, Fisher M. HMG CoA reductase inhibitors (statins): use in stroke prevention and outcome after stroke. Expert Rev. Neurother.4(2), 241–247 (2004).
   PubMed Web of Science ®Google Scholar
• Amarenco P, Moskowitz MA. The dynamics of statins: from event prevention to neuroprotection. Stroke37(2), 294–296 (2006).
   Google Scholar
• Cimino M, Gelosa P, Gianella A et al. Statins: multiple mechanisms of action in the ischemic brain. Neuroscientist13(3), 208–213 (2007).
   PubMed Web of Science ®Google Scholar
• Robinson JG, Smith B, Maheshwari N et al. Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J. Am. Coll. Cardiol.46(10),1855–1862 (2005).
   PubMed Web of Science ®Google Scholar
• Stepień K, Tomaszewski M, Czuczwar SJ. Neuroprotective properties of statins. Pharmacol. Rep.57(5), 561–569 (2005).
   PubMed Web of Science ®Google Scholar
• Vaughan CJ, Delanty N. Neuroprotective properties of statins in cerebral ischemia and stroke. Stroke30(9), 1969–1973 (1999).
   PubMed Web of Science ®Google Scholar
• Endres M, Laufs U, Huang Z et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc. Natl Acad. Sci. USA95(15), 8880–8885 (1998).
   PubMed Web of Science ®Google Scholar
• Murakami M, Fujioka S, Hirata Y et al. Low-dose of statin treatment improves cerebrovascular reactivity in patients with ischemic stroke: single photon emission computed tomography analysis. J. Stroke Cerebrovasc. Dis.17(1), 16–22 (2008).
   Google Scholar
• Sterzer P, Meintzschel F, Rösler A, Lanfermann et al. Pravastatin improves cerebral vasomotor reactivity in patients with subcortical small-vessel disease. Stroke32(12), 2817–2820 (2001).
   PubMed Web of Science ®Google Scholar
• Crisby M, Nordin-Fredriksson G, Shah PK et al. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation103(7), 926–933 (2001).
   PubMed Web of Science ®Google Scholar
• Koh KK. Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc. Res.47(4), 648–657 (2000).
   PubMed Web of Science ®Google Scholar
• Ovbiagele B, Saver JL, Starkman S et al. Statin enhancement of collateralization in acute stroke. Neurology68(24), 2129–2131 (2007).
   PubMed Web of Science ®Google Scholar
• Chen J, Zhang ZG, Li Y et al. Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann. Neurol.53(6), 743–751 (2003); Erratum, Ann. Neurol.58(5), 818 (2005).
   PubMed Web of Science ®Google Scholar
• Orr JD. Statins in the spectrum of neurologic disease. Curr. Atheroscler. Rep. (1), 11–18 (2008).
   Google Scholar
• Ponce J, de la Ossa NP, Hurtado O et al. Simvastatin reduces the association of NMDA receptors to lipid rafts: a cholesterol-mediated effect in neuroprotection. Stroke39(4), 1269–1275 (2008).
   PubMed Web of Science ®Google Scholar
• Amin-Hanjani S, Stagliano NE, Yamada M et al. Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice. Stroke32(4), 980–986 (2001).
   PubMed Web of Science ®Google Scholar
• Kawashima S, Yamashita T, Miwa Y et al. HMG-CoA reductase inhibitor has protective effects against stroke events in stroke-prone spontaneously hypertensive rats. Stroke34(1), 157–163 (2003).
   PubMed Web of Science ®Google Scholar
• Tanaka N, Katayama Y, Katsumata T et al. Effects of long-term administration of HMG-CoA reductase inhibitor, atorvastatin, on stroke events and local cerebral blood flow in stroke-prone spontaneously hypertensive rats. Brain Res.1169, 125–132 (2007).
   PubMed Web of Science ®Google Scholar
• Cakmak A, Yemişçi M, Köksoy C et al. Statin pre-treatment protects brain against focal cerebral ischemia in diabetic mice. J. Surg. Res.138(2), 254–258 (2007).
   PubMed Web of Science ®Google Scholar
• Laufs U, Gertz K, Dirnagl U et al. Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice. Brain Res.942(1–2), 23–30 (2002).
   PubMed Web of Science ®Google Scholar
• Jonsson N, Asplund K. Does pretreatment with statins improve clinical outcome after stroke? A pilot case-referent study. Stroke32(5), 1112–1115 (2001).
   PubMed Web of Science ®Google Scholar
• Martí-Fàbregas J, Gomis M, Arboix A et al. Favorable outcome of ischemic stroke in patients pretreated with statins. Stroke35(5), 1117–1121 (2004).
   PubMed Web of Science ®Google Scholar
• Reeves MJ, Gargano JW, Luo Z et al; Paul Coverdell National Acute Stroke Registry Michigan Prototype Investigators. Effect of pretreatment with statins on ischemic stroke outcomes. Stroke39(6), 1779–1785 (2008).
   Google Scholar
• Shook SJ, Gupta R, Vora NA et al. Statin use is independently associated with smaller infarct volume in nonlacunar MCA territory stroke. J. Neuroimaging16(4), 341–346 (2006).
   PubMed Web of Science ®Google Scholar
• Elkind MS, Flint AC, Sciacca RR et al. Lipid-lowering agent use at ischemic stroke onset is associated with decreased mortality. Neurology65(2), 253–258 (2005).
   PubMed Web of Science ®Google Scholar
• Greisenegger S, Müllner M, Tentschert S et al. Effect of pretreatment with statins on the severity of acute ischemic cerebrovascular events. J. Neurol. Sci.221(1–2), 5–10 (2004).
   PubMedGoogle Scholar
• Yoon SS, Dambrosia J, Chalela J et al. Rising statin use and effect on ischemic stroke outcome. BMC Med.23(2), 4 (2004).
   Google Scholar
• O’Neil-Callahan K, Katsimaglis G, Tepper MR et al. Statins decrease perioperative cardiac complications in patients undergoing noncardiac vascular surgery: the Statins for Risk Reduction in Surgery (StaRRS) study. J. Am. Coll. Cardiol.45(3), 336–342 (2005).
   PubMed Web of Science ®Google Scholar
• Kennedy J, Quan H, Buchan AM et al. Statins are associated with better outcomes after carotid endarterectomy in symptomatic patients. Stroke36(10), 2072–2076 (2005).
   PubMed Web of Science ®Google Scholar
• Kulik A, Brookhart MA, Levin R et al. Impact of statin use on outcomes after coronary artery bypass graft surgery. Circulation118(18), 1785–1792 (2008)
   PubMed Web of Science ®Google Scholar
• Sillberg VA, Wells GA, Perry JJ. Do statins improve outcomes and reduce the incidence of vasospasm after aneurysmal subarachnoid hemorrhage: a meta-analysis. Stroke39(9), 2622–2626 (2008).
   PubMed Web of Science ®Google Scholar
• Kennedy J, Hill MD, Ryckborst KJ et al.; FASTER Investigators. Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial. Lancet Neurol.6(11), 961–969 (2007).
   PubMed Web of Science ®Google Scholar
• Sironi L, Cimino M, Guerrini U et al. Treatment with statins after induction of focal ischemia in rats reduces the extent of brain damage. Arterioscler. Thromb. Vasc. Biol.23(2), 322–327 (2003).
   PubMed Web of Science ®Google Scholar
• Berger C, Xia F, Maurer MH et al. Neuroprotection by pravastatin in acute ischemic stroke in rats. Brain Res. Rev.58(1), 48–56 (2008).
   Google Scholar
• Prinz V, Laufs U, Gertz K et al. Intravenous rosuvastatin for acute stroke treatment: an animal study. Stroke39(2), 433–438 (2008).
   PubMed Web of Science ®Google Scholar
• Montaner J. Treatment with statins in the acute phase of ischemic stroke. Expert Rev. Neurother.5(2), 211–221 (2005).
   PubMedGoogle Scholar
• Montaner J, Chacón P, Krupinski J et al. Simvastatin in the acute phase of ischemic stroke: a safety and efficacy pilot trial. Eur. J. Neurol.15(1), 82–90 (2008).
   PubMed Web of Science ®Google Scholar
• Montaner J, Penalba A, Fernández-Cadenas I et al. Th1/Th2 shift induced by simvastatin in the acute phase of ischemic stroke is associated with both neurological improvement an increased risk of infections. Cerebrovasc. Dis.23(Suppl. 2), 12 (2007).
   Google Scholar
• Moonis M, Kane K, Schwiderski U et al. HMG-CoA reductase inhibitors improve acute ischemic stroke outcome. Stroke36(6), 1298–1300 (2005).
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhang ZG, Ding GL et al. Multitargeted effects of statin-enhanced thrombolytic therapy for stroke with recombinant human tissue-type plasminogen activator in the rat. Circulation112(22), 3486–3494 (2005).
   PubMed Web of Science ®Google Scholar
• Kim HH, Sawada N, Soydan G et al. Additive effects of statín and dipyridamole on cerebral blood flow and stroke protection. J. Cereb. Blood Flow Metab.28(7), 1285–1293 (2008).
   PubMedGoogle Scholar
• Alvarez-Sabín J, Huertas R, Quintana M et al. Prior statin use may be associated with improved stroke outcome after tissue plasminogen activator. Stroke38(3), 1076–1078 (2007).
   PubMed Web of Science ®Google Scholar
• Georgiadis AL, Hussein HM, Vazquez G et al. Premorbid use of statins is associated with higher recanalization rates in patients with acute ischemic stroke undergoing endovascular treatment. J. Neuroimaging19(1), 19–22 (2008).
   Google Scholar
• Bang OY, Saver JL, Liebeskind DS et al. Cholesterol level and symptomatic hemorrhagic transformation after ischemic stroke thrombolysis. Neurology68, 737–742 (2007).
   PubMed Web of Science ®Google Scholar
• Montaner J. Cholesterol measured before stroke thrombolysis is not associated with tissue plasminogen activator-related hemorrhagic transformation. Stroke39(1), E6 (2008).
   Google Scholar
• Uyttenboogaart M, Koch MW, Koopman K et al. Lipid profile, statin use, and outcome after intravenous thrombolysis for acute ischaemic stroke. J. Neurol.255(6), 875–880 (2008).
   PubMed Web of Science ®Google Scholar
• Bhindi R, Ormerod O, Newton J et al. Interaction between statins and clopidogrel: is there anything clinically relevant. QJM101(12), 915–925 (2008).
   PubMed Web of Science ®Google Scholar
• Endres M, Laufs U. Discontinuation of statin treatment in stroke patients. Stroke37(10), 2640–2643 (2006).
   Google Scholar
• Gertz K, Laufs U, Lindauer U et al. Withdrawal of statin treatment abrogates stroke protection in mice. Stroke34(2), 551–557 (2003).
   PubMed Web of Science ®Google Scholar
• Blanco M, Nombela F, Castellanos M et al. Statin treatment withdrawal in ischemic stroke: a controlled randomized study. Neurology69(9), 904–910 (2007).
   PubMed Web of Science ®Google Scholar
• Daskalopoulou SS, Delaney JA, Filion KB et al. Discontinuation of statin therapy following an acute myocardial infarction: a population-based study. Eur. Heart J.29(17), 2083–2091 (2008).
   PubMed Web of Science ®Google Scholar
• Chen J, Zhang C, Jiang H et al. Atorvastatin induction of VEGF and BDNF promotes brain plasticity after stroke in mice. J. Cereb. Blood Flow Metab.25(2), 281–290 (2005).
   PubMed Web of Science ®Google Scholar
• Sugiura S, Yagita Y, Sasaki T et al. Postischemic administration of HMG CoA reductase inhibitor inhibits infarct expansion after transient middle cerebral artery occlusion. Brain Res.1181, 125–129 (2007).
   Google Scholar
• Di Napoli M, Papa F. Inflammation, statins, and outcome after ischemic stroke. Stroke32(10), 2446–2447 (2001).
   PubMed Web of Science ®Google Scholar
• Colivicchi F, Bassi A, Santini M et al. Discontinuation of statin therapy and clinical outcome after ischemic stroke. Stroke38(10), 2652–2657 (2007).
   PubMed Web of Science ®Google Scholar
• Elkind MS, Sacco RL, MacArthur RB et al. The Neuroprotection with Statin Therapy for Acute Recovery Trial (NeuSTART): an adaptive design phase I dose-escalation study of high-dose lovastatin in acute ischemic stroke. Int. J. Stroke3(3), 210–218 (2008).
   PubMed Web of Science ®Google Scholar
• Endres M. Statins and stroke. J. Cereb. Blood Flow Metab.25(9), 1093–1110 (2005).
   PubMed Web of Science ®Google Scholar
• Zlokovic BV. Remodeling after stroke. Nat. Med.12, 390–391 (2006).
   PubMed Web of Science ®Google Scholar